The third quarter of 2025 was the moment the psychedelic thesis stopped being a promise and started printing pivotal data. Compass Pathways and MindMed both put late-stage results on the table, Reunion Neuroscience delivered a clean Phase 2 win in postpartum depression, and — in the quarter's defining event — AbbVie agreed to pay up to $1.2 billion for a psychedelic asset, the loudest signal yet that Big Pharma is done watching from the sidelines.
This report walks through the clinical, regulatory, and capital-markets developments that defined Q3 2025, and closes with what they mean for the quarters ahead.
Index Performance
The Psychedelic Invest Index (GPI) gained +22.8% across the third quarter of 2025, moving from 151.9 on 2025-06-30 to 186.6 on 2025-09-30. It ranged from an intraperiod low of 141.6 (2025-07-15) to a high of 186.9 (2025-09-29). Track the live index and its constituents on our Stock Index page.
Clinical & Pipeline Milestones
The engine of the sector remains its clinical readouts. Here are the trial results, regulatory designations, and pipeline milestones that moved the needle this period.
Enveric Biosciences (ENVB). Enveric Biosciences reported that a single oral dose of EB-003, its non-hallucinogenic neuroplastogen candidate, significantly reduced context-induced freezing behavior in fear-conditioned mice measured one hour post-dose (p<0.05). The company framed the result as evidence of accelerated extinction of contextual fear, supporting EB-003's potential in PTSD. As an early preclinical readout, it helps build the rationale for advancing the program toward the clinic for a small-cap developer.
Clearmind Medicine (CMND). Clearmind Medicine activated a new clinical site at Johns Hopkins University School of Medicine and enrolled its first participant there in the Phase I/IIa trial of CMND-100, its MEAI-based oral candidate for alcohol use disorder. The addition followed the enrollment of a first patient at Yale, extending the multinational, multicenter study assessing safety, tolerability, pharmacokinetics and early signals of reduced cravings and consumption. Broadening top-tier US sites is a visibility and execution milestone for the micro-cap.
Cybin Inc. (CYBN). Cybin said the UK's MHRA cleared it to start EMBRACE, the second pivotal study in its multinational Phase 3 PARADIGM program for CYB003, a deuterated psilocin analog carrying FDA Breakthrough Therapy Designation. EMBRACE is designed to enroll 330 patients with major depressive disorder who respond inadequately to antidepressants, randomizing them to CYB003 16 mg, 8 mg, or placebo across two doses given three weeks apart. The clearance expands the Phase 3 program beyond the US into UK and European sites and keeps Cybin's late-stage timeline on track.
Reunion Neuroscience. Reunion Neuroscience announced peer-reviewed publication of Phase 1 data for RE104, its subcutaneous, shorter-duration serotonergic psychedelic prodrug. The publication supported RE104's pharmacology and tolerability profile ahead of its Phase 2 RECONNECT study in postpartum depression. For the private developer, the journal placement adds scientific credibility to a differentiated, shorter-acting candidate.
GH Research (GHRS). GH Research outlined plans for a global pivotal program for GH001, its inhaled 5-MeO-DMT (mebufotenin) candidate, and released its complete Phase 2b treatment-resistant depression dataset, including a placebo-adjusted 15.5-point MADRS reduction at Day 8 (p<0.0001) and a 73% six-month remission rate in the open-label extension without mandated psychotherapy. The company said only one topic remains on its US FDA clinical hold, tied to respiratory-tract histology findings in rats. The update maps GHRS's path toward Phase 3 while flagging the IND hold as the key US gating item.
Clearmind Medicine (CMND). Clearmind Medicine completed initiation of a leading Israeli clinical site for its Phase I/IIa trial of CMND-100 in alcohol use disorder, adding to previously activated US sites at Yale and Johns Hopkins. The expansion widened the multinational footprint of the study evaluating safety, dosing and early efficacy signals such as reduced alcohol cravings and consumption. Consistent site build-out is an operational marker of progress for the small-cap.
atai Life Sciences (ATAI). atai Life Sciences stock slid around 9% in premarket trading after Recognify Life Sciences, an atai-backed company, reported that its Phase 2b trial of inidascamine for cognitive impairment associated with schizophrenia missed its primary endpoint. The setback was a reminder of pipeline risk in atai's broader portfolio even as its lead 5-MeO-DMT program with Beckley Psytech advanced. Investors reacted to the miss as a negative read-through for that non-psychedelic asset.
Psyence Biomedical (PBM). Psyence Biomedical said its strategic partner PsyLabs produced a GMP-aligned ibogaine total-alkaloid extract that met microbial safety standards in third-party testing. The milestone positions the company in the ibogaine supply chain amid rising US policy interest in ibogaine for addiction and veterans' mental health. It gives the small-cap a potential ingredient-supply angle for future clinical and research demand.
Cybin Inc. (CYBN). Cybin disclosed via an SEC filing that CEO Doug Drysdale would take part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston. The appearance kept the company in front of institutional investors ahead of its fiscal Q1 2026 results and continued progress on the CYB003 Phase 3 EMBRACE study. It is a routine investor-relations event rather than a clinical catalyst.
NRx Pharmaceuticals (NRXP). NRx Pharmaceuticals said the FDA granted an expanded Fast Track designation (received August 8) for NRX-100, its preservative-free IV ketamine, covering suicidal ideation in patients with depression including bipolar depression. The company said the broader label roughly ten-times the addressable population versus its original 2017 designation, to about 13 million Americans, and argued the agency's unmet-need finding supports eligibility for the Commissioner's National Priority Voucher program as it pursues an NDA.
Reunion Neuroscience. Reunion Neuroscience reported positive topline results from its Phase 2 RECONNECT trial of RE104 in postpartum depression, with a single 30 mg subcutaneous dose producing a 23.0-point MADRS reduction at Day 7 versus 17.2 points for the 1.5 mg active control (p=0.0094). Response rate was 77.1% for the 30 mg arm versus 61.6% for control, with effects maintained through Day 28 across 84 patients at 38 US sites. The clean win in a fast-acting, shorter-duration psychedelic strengthens the private company's differentiated late-stage prospects.
Incannex Healthcare (IXHL). Incannex Healthcare reported positive Phase 2 data for PSX-001, a psilocybin-assisted psychotherapy for generalized anxiety disorder, in a 73-patient randomized, placebo-controlled trial using two 25 mg dosing sessions. Roughly 44% of PSX-001 patients achieved at least a 50% reduction in anxiety scores and 27% reached remission, a remission rate more than five times that of placebo, with no serious adverse events and only one withdrawal. The clean efficacy and safety profile advances Incannex's psilocybin program toward late-stage development.
atai Life Sciences (ATAI). atai Life Sciences said management would appear at several investor conferences in September 2025. The circuit gave the company a platform to make its case to institutional investors as it advanced its planned strategic combination with Beckley Psytech, which it had guided toward a shareholder-approval stage in Q4 2025 following July's positive BPL-003 Phase 2b topline. It is an investor-relations event rather than a clinical catalyst.
Compass Pathways (CMPS). Compass Pathways announced publication of an open-label Phase 2 study of a single 25 mg dose of its synthetic psilocybin candidate COMP360 in 22 patients with PTSD. The data showed COMP360 was well tolerated with rapid and durable symptom improvement out to 12 weeks after a single dose. The findings support a potential second indication beyond treatment-resistant depression, where Compass reported positive Phase 3 topline results earlier in 2025.
Source: ir.compasspathways.com
Mind Medicine (MindMed) (MNMD). The Journal of the American Medical Association published full results from MindMed's Phase 2b study of MM120 (lysergide D-tartrate) in 198 adults with moderate-to-severe generalized anxiety disorder. The trial tested single monotherapy doses of 25, 50, 100 and 200 micrograms without study-related psychotherapy and found dose-dependent anxiety reductions durable through week 12, with mostly mild-to-moderate dosing-day adverse events. The peer-reviewed publication validates the 100 microgram dose selected for MindMed's three ongoing Phase 3 trials and lends prominence to the Breakthrough Therapy-designated program.
Cybin Inc. (CYBN). Cybin disclosed via an SEC Form 6-K that Chief Business Officer George Tziras would take part in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The appearance followed Cybin's August $50 million convertible debenture financing and its MHRA/European approvals to begin the EMBRACE pivotal study of CYB003. It is a routine investor-relations event rather than a clinical catalyst.
Cybin Inc. (CYBN). Cybin finished enrolling its Phase 2 trial of CYB004, a proprietary deuterated DMT candidate, in patients with generalized anxiety disorder. The study enrolled 36 participants and assesses safety and efficacy at 12 weeks after the first dose, with topline data reaffirmed for the first quarter of 2026. The milestone keeps Cybin's second clinical program on schedule alongside its lead CYB003 depression asset.
Sector coverage (AbbVie / Gilgamesh, Compass Pathways) (CMPS). A STAT feature analyzed why large drugmakers are warming to psychedelics after AbbVie's late-August agreement to buy Gilgamesh Pharmaceuticals' bretisilocin for up to $1.2 billion, the first purchase of an investigational psychedelic by a major pharma company. Compass Pathways CEO Kabir Nath called the deal validation for the sector. The piece framed a shift in sentiment that investors in public names like Compass, Cybin and atai were watching closely.
Reunion Neuroscience Inc. (Private). Reunion Neuroscience announced the final closing of its Series A, with the last tranche increasing from $21 million to $51 million to bring the round to $133 million. The upsize was triggered after its RECONNECT study of RE104 in postpartum depression met pre-set efficacy criteria. Proceeds fund the ongoing REKINDLE Phase 2 trial in adjustment disorder and expansion of RE104 into generalized anxiety disorder.
atai Life Sciences N.V. (ATAI). atai received a multi-year, milestone-based grant worth up to $11.4 million from the National Institute on Drug Abuse (part of NIH) to develop novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder. The funding supports lead optimization, proof-of-concept studies and IND-enabling work. atai framed it as the first external validation of its AI-driven drug discovery approach.
atai Life Sciences / Beckley Psytech (ATAI). The partners reported positive results from an open-label Phase 2a study of a two-dose induction regimen of BPL-003 (intranasal mebufotenin/5-MeO-DMT) in treatment-resistant depression. Among 12 evaluable patients, a second dose drove a mean MADRS reduction of 19.0 points, with remission rising from 25% to 50% at Week 8 and effects sustained through Week 12. The data support a planned Phase 3 program expected to begin in the first half of 2026.
NRx Pharmaceuticals, Inc. (NRXP). NRx Pharmaceuticals said the FDA granted its suitability petition for the proposed strength of its single-patient, preservative-free ketamine product (marketed as KETAFREE). The approval clears a procedural step supporting NRx's planned NDA for NRX-100 (IV ketamine) in suicidal depression, a program that holds Fast Track designation. It advances the company's path toward a potential 2026 regulatory decision.
Policy, Regulation & Access
Psychedelic policy accelerated on multiple fronts — federal, state, and international. These developments shape the demand-side runway for every developer we track.
Filament Health / German health authorities (FH). Germany's federal drug regulator (BfArM) authorized a compassionate-use program allowing adults with treatment-resistant depression to receive psilocybin, the first time a psychedelic has been made available under expanded-access rules in the EU. The botanical psilocybin drug candidate PEX010 is supplied by Canada's Filament Health, initially through two centers, the Central Institute of Mental Health and OVID Clinic Berlin, with capacity for roughly 50 patients in the first year. For investors, the program gives Filament an early European supply foothold and signals growing regulator willingness to permit supervised psilocybin access outside formal trials.
State of Texas (ibogaine policy). A July 14 report examined Texas's decision, via Senate Bill 2308, to commit up to $50 million in grants for FDA-supervised ibogaine research, described as the largest state investment of its kind and requiring a private-sector match. The program creates a consortium of universities, hospitals and drug developers to run trials targeting PTSD and addiction. The funding is a potential catalyst for ibogaine-focused developers seeking clinical partners and non-dilutive capital.
Source: americanhomefront.wunc.org
Germany (psilocybin policy). Forbes published a detailed August 7 account of Germany's newly launched compassionate-use program giving treatment-resistant depression patients supervised access to psilocybin, the first such access route in the EU. The coverage underscored the role of Filament Health's PEX010 and the initial capacity constraints at participating clinics. The high-profile reporting extended sector attention to a policy development seen as a template for broader European access.
Colorado Natural Medicine Advisory Board (policy). Colorado's Natural Medicine Advisory Board voted 5-2 to recommend therapeutic access to ibogaine within the state's regulated natural medicine framework. If adopted, Colorado would become the first U.S. state with licensed ibogaine facilities, though access is contingent on compliance with the Nagoya Protocol governing sourcing. The move signals expanding state-level psychedelic policy beyond psilocybin.
Capital Markets, M&A & Corporate
Financings, listings, and dealmaking tell you where conviction is flowing. This is how the sector's balance sheets and corporate structures shifted.
Compass Pathways (CMPS). Compass Pathways reported a Q2 2025 net loss of $38.4 million ($0.41 per share) and ended June with $221.9 million in cash, providing runway into 2027. Following a positive primary-endpoint readout in its first COMP360 psilocybin Phase 3 trial in treatment-resistant depression, management said it was evaluating options for a potentially accelerated regulatory filing. The second pivotal Phase 3 trial continued enrolling, with 26-week data expected in the second half of 2026.
Mind Medicine (MindMed) (MNMD). MindMed reported a Q2 2025 net loss of $42.7 million as R&D roughly doubled year-over-year to $29.8 million, reflecting three Phase 3 trials of MM120 ODT (LSD) in generalized anxiety disorder and major depressive disorder. Cash and investments were $237.9 million at June 30, funding operations into 2027 and past the first Phase 3 topline. Voyage topline data was expected in the first half of 2026, with Panorama and Emerge to follow; the company also named Brandi L. Roberts as CFO.
GH Research (GHRS). GH Research reported a Q2 2025 net loss of $9.3 million and cash of $308.7 million. The company said its full open-label extension analysis for GH001 (inhaled 5-MeO-DMT) in treatment-resistant depression confirmed a 73% remission rate at six months without mandated psychotherapy and no treatment-related serious adverse events. It reiterated that only one topic remained on the GH001 IND clinical hold and that it planned to start its global pivotal program in 2026.
Cybin Inc. (CYBN). Cybin reported results for its fiscal first quarter ended June 30, 2025, with $118.7 million in cash bolstered by a recent $50 million convertible debenture financing. The company highlighted European and UK MHRA approvals for EMBRACE, the second pivotal study of CYB003 (deuterated psilocin) as adjunctive treatment for major depressive disorder, spanning 330 participants across roughly 60 sites. Enrollment completion in the CYB004 (DMT) Phase 2 generalized anxiety disorder study was expected in August 2025.
atai Life Sciences (ATAI). atai Life Sciences cut its Q2 2025 net loss to $27.7 million from $57.4 million a year earlier, while cash, equivalents and short-term securities rose to $95.9 million. With an additional $50 million in committed funding announced in July, management said combined-company resources should fund operations into the second half of 2027 as it advances its planned strategic combination with Beckley Psytech, whose BPL-003 (intranasal 5-MeO-DMT) recently delivered positive Phase 2b treatment-resistant depression data.
Cybin Inc. (CYBN). Cybin held its annual general meeting in Toronto on August 18, 2025, with holders of about 11.26 million shares (roughly 49% of shares outstanding) represented. Shareholders elected all director nominees and reappointed Zeifmans LLP as auditor. The routine governance vote followed the company's fiscal Q1 2026 report detailing a $50 million convertible financing and $118.7 million in cash.
AbbVie / Gilgamesh Pharmaceuticals (ABBV). AbbVie agreed to acquire Gilgamesh Pharmaceuticals' lead asset bretisilocin (GM-2505), a short-acting 5-HT2A agonist and serotonin releaser in Phase 2 development for major depressive disorder, in a deal worth up to $1.2 billion in upfront and milestone payments. A Phase 2a trial had shown a single 10 mg dose meaningfully reduced depressive symptoms versus a low-dose comparator. As one of the largest big-pharma commitments to a psychedelic asset to date, the deal was widely read as validation for the sector and lifted publicly traded peers.
What to Watch
Heading into the fourth quarter, three things are worth watching: whether GH Research can clear the last item on its FDA clinical hold, whether the atai–Beckley combination closes on schedule, and whether the AbbVie/Gilgamesh deal pulls additional strategic buyers into the sector. The read-through from a single $1.2 billion transaction is that validated, de-risked psychedelic assets now have credible acquirers — which reprices the entire development-stage cohort.
This report is compiled by Psychedelic Invest from primary company disclosures and industry reporting; each story links its source. It is provided for informational purposes only and is not investment advice.